Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > G12D/G12V KRAS mutation in PC & CRC patients respond to Pela

<< Previous

Bullboard Posts

Next >>

Comment by CMHarring218431on Jul 28, 2024 7:08pm

85 Views

Post# 36151932

RE:RE:RE:RE:RE:RE:RE:RE:RE:G12D/G12V KRAS mutation in PC & CRC patients respond to Pela

Dr Ajay Goel , M.S., Ph.D is more than a poet and proponent of natural food remedies. He has quite the reputation as a cancer researcher and his clinical research has proven the the effectiveness of botanical medicines in helping to prevent multiple cancers. His work is definitely worth a look imo

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario